Ukko

About:

Ukko is a biotech company improving the lives of millions that suffer from food allergies and disorders.

Website: https://www.ukko.us/

Twitter/X: Ukko_Inc

Top Investors: Khosla Ventures, Fall Line Capital, Leaps by Bayer, Innovation Endeavors, PeakBridge

Description:

Ukko is a biotech company improving the lives of millions that suffer from food allergies and disorders. The company's computational engineering platform re-designs food allergens into safe and effective therapeutics that will become best-in-class allergy therapy. Ukko is creating a comprehensive, clinically validated map of the molecular structure of food allergies, revealing critical information about the biological mechanisms that govern human-food interactions. They use the platform to create new versions of proteins that do not elicit an immune response based on this map. These proteins enable a completely new approach to treating protein-based allergies.

Total Funding Amount:

$47.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Palo Alto, California, United States

Founded Date:

2016-01-01

Contact Email:

info(AT)ukko.us

Founders:

Anat Binur

Number of Employees:

11-50

Last Funding Date:

2021-01-27

IPO Status:

Private

Industries:

© 2025 bioDAO.ai